Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05508399
Other study ID # Gang Ji -2
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 18, 2022
Est. completion date July 18, 2026

Study information

Verified date August 2023
Source Xijing Hospital
Contact Gang Ji, Doctoral
Phone +8618153227717
Email xijingweichang@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

G/GEJ adenocarcinoma is one of the most common malignant tumors in China, ranking the fifth highest incidence and third highest mortality worldwide. Currently, surgical resection is the preferred treatment for G/GEJ adenocarcinoma, while the 5-year survival rate of patients is lower than 25%. Compared with surgical resection, immunotherapy is proved to be able to effectively prolong the survival time of patients. On one hand, with the continuous promotion of immunotherapy drugs, the exploration of neoadjuvant application of immunotherapy in G/GEJ adenocarcinoma has become a hotspot in recent years. It's also on their way that clinical trials of programmed death receptor-1 (PD-1), programmed death ligand-1 (PD-L1) and other immune checkpoints are carried out. On the other hand, the research found that although the curative effect of immune therapy seems better, the present G/GEJ adenocarcinoma immunotherapy marker researches mainly focused on the late stage of the cancer, with few studies of immune markers of neoadjuvant therapy for G/GEJ adenocarcinoma. Additionally, it's not quite feasible for single biomarkers to predict the immune treatment effect precisely. Therefore, combined with clinicopathology and therapeutic effects, this study is aimed to construct the efficacy prediction model of anti-PD-1 antibody together with chemotherapy for G/GEJ adenocarcinoma, by detecting RNA expression. Furthermore, this study will perform drug sensitivity test and bio-molecular test on patient derived organoid model to validate the biomarkers found from biological specimens.


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date July 18, 2026
Est. primary completion date July 18, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Aged 18-80 (including 18 and 80); 2. G/GEJ adenocarcinoma confirmed by basic ultrasound gastroscopy, enhanced CT (PET/CT), MRI or diagnostic laparoscopy; 3. Biopsy histologically confirmed adenocarcinoma 4. As assessed by the investigator, patients who are qualified for receiving PD-1 mab combined with chemotherapy neoadjuvant therapy; 5. Patients who volunteer to participate in this study and sign the informed consent, with good compliance and cooperation in the acquisition of biological specimens. Exclusion Criteria: 1. Patients whose biological specimens do not meet the detection standards; 2. In the judgment of the investigator, the patients with factors that might have caused the study to be terminated.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
DNA panel and RNA Sequencing
Interventions include collecting samples, DNA panel test and full transcriptome sequencing. Before collecting samples, obtaining written informed consent from patient in advance. Blood cell samples; Paraffin sample of residual tumor tissue of biopsy; Paraffin sample of residual tumor tissue and paracancer tissue after gastrectomy.

Locations

Country Name City State
China Xijing Hospital of Digestive Diseases Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Relative RNA biomarkers At the RNA level, to identify the biomarkers related to the efficacy of neoadjuvant therapy with PD-1 mab combined with chemotherapy in locally advanced gastric cancer. From the initiation date of patients recruited into groups to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Primary Prediction model for efficacy A prediction model for the efficacy of PD-1 mab combined with chemotherapy, constructed on the basis of clinical pathology, gene variation, gene expression and other factors. From the date of completing collecting data, to the date of death from any cause or the end date of the whole trail, whichever came first, assessed up to 2 years
Secondary Conditions of immune microenvironment To monitor the changes of immune microenvironment before and after neoadjuvant treatment with PD-1 mab combined with chemotherapy for locally advanced gastric cancer. To evaluate whether the tumor infiltration immune cell and organoid co-cultural system can rebuild the tumor immune micro-environment, the immune cell subpopulations will be detected by single-cell sequencing, immunofluorescence staining and flow-cytometry. From the initiation date of patients recruited into groups to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Secondary Drug resistance mechanism To explore the drug resistance mechanism of locally advanced gastric cancer after neoadjuvant therapy with PD-1 mab combined with chemotherapy. From the initiation date of patients recruited into groups to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Secondary Response of organoids to the same neoadjuvant drugs as the corresponding patients The investigators will establish the G/GEJ adenocarcinoma organoid and tumor infiltration immune cell co-cultural model. The model will be treated with the same PD-1 mab combined with chemotherapy drugs as the corresponding patients. The viability of the organoids will be observed and quantified after treatment. The correlation of 3D organoid sensitivity and the patient response will be analyzed. And RNA expression detection of organoids before and after treatment will be performed to further validate the biomarkers from biological specimens. From the initiation date of patients recruited into groups to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06130332 - Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) Phase 2
Recruiting NCT06250894 - Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction Phase 2
Recruiting NCT04778956 - Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma Phase 3
Not yet recruiting NCT05741021 - A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase 2
Not yet recruiting NCT04284202 - PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC Phase 2
Recruiting NCT04615988 - Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
Active, not recruiting NCT04906044 - Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer Phase 1
Not yet recruiting NCT04690036 - PD-1 Antibody for Reactive EBV After BMT Early Phase 1
Recruiting NCT05980715 - PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy Phase 3
Recruiting NCT04840355 - Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients
Recruiting NCT04191252 - Genetic Mutation in Epithelial Ovarian Cancer
Recruiting NCT04191226 - Genetic Mutation in Recurrent Cervical Cancer
Not yet recruiting NCT04061928 - Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ Phase 1/Phase 2
Recruiting NCT05979740 - RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Phase 2
Recruiting NCT05980702 - 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC Phase 2
Not yet recruiting NCT04814069 - A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinomaļ¼šThe POTENTIAL Study Phase 2